Real Research, Real Results. Together We Can Cure Cancer.

The Sbarro Health Research Organization (SHRO) is a nonprofit charity committed to funding excellence in basic genetic research to cure and diagnose cancer, cardiovascular diseases, diabetes and other chronic illnesses and to foster the training of young doctors in a spirit of professionalism and humanism. In 1993, Antonio Giordano, M.D., Ph.D., founded the Sbarro Institute with a generous donation from Mario Sbarro, the Founder of the Sbarro restaurant chain, following Dr. Giordano’s discovery of the tumor suppressor gene pRb2. Initially named the Sbarro Institute, the research center was located at Thomas Jefferson University, where Dr. Giordano was a professor.
Antonio Giordano

Message from Dr. Antonio Giordano – Founder of SHRO

“Think of genetic research as language. We have identified the words; now we are constructing the dictionary and learning the rules of grammar. Our task is to continue assembling the dictionary and perhaps the construction of a few grammatically accurate sentences. The goal is to eventually add new chapters to the novel of life”

Latest Posts

Post & News

Among the causes of type 1 diabetes is a newly discovered bacterium

Among the causes of type 1 diabetes is a newly discovered bacterium Among the causes of type 1 diabetes is…
Read More
Post & News

Predicting Outcomes for Rare Form of Bladder Cancer with Metastatic Tumors

Original Newswise post Newswise — A team of investigators from the Sbarro Institute for Cancer Research and Molecular Medicine, and…
Read More
Post & News

Molecular Medicine Review Reveals the Role of IGF in Cancer, Other Proliferative Disease

Original Newswise post Newswise — Studies suggest that Insulin-Like Growth Factor (IGF) plays a central role in pathological growth of…
Read More
Post & News

Immunotherapy Covered in Special Edition of Current Clinical Pathology

Newswise — In the latest Current Clinical Pathology publication on Immunotherapy, Sbarro Health Research Organization (SHRO) President, Antonio Giordano, M.D., Ph.D., co-edits…
Read More
Post & News

‘One Health’ Approach Is Necessary to Address Rising Environmental Causes of Childhood Cancers

Editorial by Prof. Philip Landrigan, Director of the Global Public Health Programme, published in the second issue of Annals of…
Read More
Uncategorized

VR-Integrated Rehab for Cancer Patients Shows Potential in Research Review

Newswise press release — Oncology researchers using Virtual Reality (VR) in the treatment of cancer patients have published a review of the…
Read More
Post & News

(SHRO) Drug Repurposing Identifies New Candidates to Treat Mesothelioma

Newswise — A group of researchers including Antonio Giordano, M.D., Ph.D., Director and Founder of the Sbarro Health Research Organization…
Read More
Post & News

Treatment with Cell Cycle Inhibitors: Another Caveat on a Clinical Trial for Mesothelioma Red-Flagged in Lancet Oncology

Original Newswise post There is a growing awareness that the design of clinical trials can be misleading and provide evidence…
Read More
Post & News

Sbarro Health Research Organization (SHRO) Arrives in Campania

  “If I have seen further it is by standing on the shoulders of Giants” – Sir Isaac Newton (in…
Read More
Post & News

Researchers Call for More Transparency from Russia’s Sputnik COVID Vaccine

“It is not a problem connected to “the Sputnik V” vaccine itself,” argues Prof. Enrico Bucci, adjunct professor in the…
Read More
Post & News

SHRO’s Giordano Meets with Speaker Pelosi at Italian Embassy in Washington

Newswise — WASHINGTON, D.C. May 19, 2021—At the prestigious setting of Villa Firenze, the Italian Embassy in Washington, DC, on…
Read More
Post & News

Inflammation and Procalcitonin Predict Success, or Not, of Lung Cancer Treatment

In patients with non-small cell Lung Cancer (NSCLC), the presence of either high chronic inflammation, or procalcitonin levels in the…
Read More
Post & News

The Medicine in Eye Drops Needs a Disguise to Sneak Past Your Tears

Scientists use engineered protein coating that binds to receptors on the surface of corneal cells to improve drug uptake. The…
Read More
Scroll to Top